Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
AssigneeApotex Pharmachem Inc.
InventorsPrabhudas Bodhuri, Gamini Weeratunga
Life of this patent
Estimating the term…
Abstract
A polymorphic form of rivaroxaban, 5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxa-zolidin-5-yl]-methyl}thiophene-2-carboxamide (termed form APO-A), processes for the preparation thereof, and compositions and formulations comprising form APO-A are provided. Also provided are compositions comprising a crystalline form of rivaroxaban and solvents selected from C3 to C6 ketones, C3 to C4 amides and mixtures thereof.
Claims521
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 39.12 degrees two-theta.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta plus or minus 0.2 degree two-theta.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 34.60 degrees two-theta.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta plus or minus 0.2 degree two-theta.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 39.12 degrees two-theta with a relative intensity of at least about 8.72%.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta plus or minus 0.2 degree two-theta with a relative intensity of at least about 8.72%.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta with a relative intensity of at least about 8.72%.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 34.60 degrees two-theta with a relative intensity of at least about 8.45%.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta plus or minus 0.2 degree two-theta with a relative intensity of at least about 8.45%.
A polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta with a relative intensity of at least about 8.45%.
A process for the preparation of form APO-A comprising:
- a. combining a compound of formula (1):
- with an organic solvent or a mixture of solvents to form a mixture;
- b. heating the mixture;
- C. removing undissolved solid to form a solution;
- d. promoting crystal growth;
- and
- e. collecting crystals.
A product comprising form APO-A made by a process comprising:
- a. combining a compound of formula (1):
- with an organic solvent or a mixture of solvents to form a mixture;
- b. heating the mixture;
- C. removing undissolved solid to form a solution;
- d. promoting crystal growth;
- and
- e. collecting crystals.
A pharmaceutical formulation comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 39.12 degrees two-theta.
A pharmaceutical formulation comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta plus or minus 0.2 degree two-theta.
A pharmaceutical formulation comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta.
A pharmaceutical formulation comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 34.60 degrees two-theta.
A pharmaceutical formulation comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta plus or minus 0.2 degree two-theta.
A pharmaceutical formulation comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 39.12 degrees two-theta and another polymorphic form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta plus or minus 0.2 degree two-theta and another polymorphic form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta and another polymorphic form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 34.60 degrees two-theta and another polymorphic form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta plus or minus 0.2 degree two-theta and another polymorphic form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta and another polymorphic form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 39.12 degrees two-theta and an amorphous form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta plus or minus 0.2 degree two-theta and an amorphous form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta and an amorphous form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 34.60 degrees two-theta and an amorphous form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta plus or minus 0.2 degree two-theta and an amorphous form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta and an amorphous form of rivaroxaban.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 39.12 degrees two-theta and methyl-isobutylketone.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta plus or minus 0.2 degree two-theta and methyl-isobutylketone.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 39.12 degrees two-theta and methyl-isobutylketone.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at about 34.60 degrees two-theta and methyl-isobutylketone.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta plus or minus 0.2 degree two-theta and methyl-isobutylketone.
A composition comprising a polymorphic form of rivaroxaban characterized by an X-ray diffraction pattern comprising a peak at 34.60 degrees two-theta and methyl-isobutylketone.
A composition comprising a crystalline form of rivaroxaban and an organic solvent selected from the group consisting of:
- C3 to C6 ketones, C3 to C4 amides and mixtures thereof.
Dependencies are inferred from the claim text.